Cantor Fitzgerald upgraded Verve Therapeutics (VERV) to Overweight from Neutral.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Buy Rating for Verve Therapeutics: Promising Safety and Efficacy of VERVE-102 in Phase 1b Heart-2 Study
- Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102
- Verve Therapeutics receives FDA Fast Track designation for VERVE-102
- Biotech stocks slide as Marks resignation seen being negative for sector
